Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

Holmes, F A; Walters, R S; Theriault, R L; Forman, A D; Newton, L K; Raber, M N; Buzdar, A U; Frye, D K; Hortobagyi, G N.

J Natl Cancer Inst ; 83(24): 1797-805, 1991 Dec 18.

Artículo en Inglés | MEDLINE | ID: mdl-1683908

2.

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.

Hortobagyi, G N; Buzdar, A U; Theriault, R L; Valero, V; Frye, D; Booser, D J; Holmes, F A; Giralt, S; Khouri, I; Andersson, B; Gajewski, J L; Rondon, G; Smith, T L; Singletary, S E; Ames, F C; Sneige, N; Strom, E A; McNeese, M D; Deisseroth, A B; Champlin, R E.

J Natl Cancer Inst ; 92(3): 225-33, 2000 Feb 02.

Artículo en Inglés | MEDLINE | ID: mdl-10655439

3.

Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.

Diamandidou, E; Buzdar, A U; Smith, T L; Frye, D; Witjaksono, M; Hortobagyi, G N.

J Clin Oncol ; 14(10): 2722-30, 1996 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-8874333

4.

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.

Rahman, Z U; Frye, D K; Buzdar, A U; Smith, T L; Asmar, L; Champlin, R E; Hortobagyi, G N.

J Clin Oncol ; 15(10): 3171-7, 1997 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9336352

5.

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.

Hortobagyi, G N; Bodey, G P; Buzdar, A U; Frye, D; Legha, S S; Malik, R; Smith, T L; Blumenschein, G R; Yap, H Y; Rodriguez, V.

J Clin Oncol ; 5(3): 354-64, 1987 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-3819804

6.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

Buzdar, A U; Singletary, S E; Theriault, R L; Booser, D J; Valero, V; Ibrahim, N; Smith, T L; Asmar, L; Frye, D; Manuel, N; Kau, S W; McNeese, M; Strom, E; Hunt, K; Ames, F; Hortobagyi, G N.

J Clin Oncol ; 17(11): 3412-7, 1999 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-10550135

7.

Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine.

Holmes, F A; Lopez, A; Mavligit, G; Fraschini, G; Frye, D; Hortobagyi, G N.

Int J Cancer ; 73(2): 184-6, 1997 Oct 09.

Artículo en Inglés | MEDLINE | ID: mdl-9335439

8.

The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy.

Kinney, A Y; Sahin, A; Vernon, S W; Frankowski, R F; Annegers, J F; Hortobagyi, G N; Buzdar, A U; Frye, D K; Dhingra, K.

Cancer ; 80(12): 2240-9, 1997 Dec 15.

Artículo en Inglés | MEDLINE | ID: mdl-9404700

9.

Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy.

Rivera, E; Holmes, F A; Frye, D; Valero, V; Theriault, R L; Booser, D; Walters, R; Buzdar, A U; Dhingra, K; Fraschini, G; Hortobagyi, G N.

Cancer ; 89(11): 2195-201, 2000 Dec 01.

Artículo en Inglés | MEDLINE | ID: mdl-11147589

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar: